Competitor Watch
Monitor competitor pipelines, recent approvals, and strategic moves in the pharma industry.
Summary: Pfizer has 5 drugs in late-stage development, 2 recent FDA approvals, and is expanding in oncology and vaccines. Recent moves: Acquisition of Seagen, launch of RSV vaccine Abrysvo.
| Drug | Indication | Status | Recent Milestone |
|---|---|---|---|
 Abrysvo |
RSV | FDA Approved | Launched Q3 2025 |
| Talzenna |
Breast Cancer | Phase 3 | Phase 3 data published Jan 2026 |
| Vyndaqel |
ATTR-CM | FDA Approved | Label expansion Q4 2025 |
| PF-07284892 |
Solid Tumors | Phase 2 | First patient dosed Dec 2025 |
Recent Approvals
- Abrysvo (RSV) – FDA approved Q3 2025
- Vyndaqel (ATTR-CM) – Label expansion Q4 2025
Strategic Moves
- Acquisition of Seagen (Oncology)
- Expansion in vaccines (RSV, COVID-19)
- Partnership with BioNTech